The clinical significance of atypical indirect immunofluorescence patterns on primate cerebellum in paraneoplastic antibody screening
- PMID: 32257062
- PMCID: PMC7065332
- DOI: 10.1186/s13317-019-0116-6
The clinical significance of atypical indirect immunofluorescence patterns on primate cerebellum in paraneoplastic antibody screening
Abstract
Purpose: Screening for paraneoplastic antibodies is often performed by means of indirect immunofluorescence on primate cerebellar slices. However, atypical immunofluorescence patterns, i.e. patterns that are not specifically related to paraneoplastic antibodies, are often reported. The clinical significance of these patterns is not clear. Therefore, the purpose of this study was to determine the significance and diagnostic value-in terms of a paraneoplastic neurological syndrome or other neurological disease being diagnosed in the patient-of such atypical immunofluorescence screening patterns on primate cerebellum.
Methods: This study is a retrospective single center study including atypical indirect immunofluorescence screening patterns of patients with a negative or absent typing assay for intraneuronal and anti-amphiphysin paraneoplastic antibodies. Patients with a positive typing assay or without final diagnosis were excluded. Included patients were grouped according to (i) reported immunofluorescence pattern and (ii) established diagnosis, after which contingency table analyses were performed to investigate an interrelation between reported pattern and diagnostic group.
Results: In 3.7% of cases, patients with an atypical pattern obtained a final diagnosis of a paraneoplastic neurological syndrome. The presence of atypical patterns was more prominent in patients with epilepsy or peripheral neuropathies (p Monte Carlo simulation = 0.026), without, however, adding any diagnostic information.
Conclusions: An atypical indirect immunofluorescence pattern on primate cerebellum in the screening for paraneoplastic antibodies has only very minor relevance with respect to paraneoplastic neurological syndromes or any other neurological disease, recommending clinicians to interpret the results of positive screening assays for such antibodies with care.
Keywords: Antineuronal antibodies; Indirect immunofluorescence; Paraneoplastic neurological syndromes; Primate cerebellum; Screening assay.
© The Author(s) 2019.
Conflict of interest statement
Competing interestsThe authors declare that they have no competing interests.
Figures


Similar articles
-
Diagnostic accuracy of different immunological methods for the detection of antineuronal antibodies in paraneoplastic neurological syndromes.Immunol Invest. 2010 Jan;39(2):186-95. doi: 10.3109/08820130903513431. Immunol Invest. 2010. PMID: 20136624
-
Paraneoplastic neurological antibodies: a laboratory experience.Ann N Y Acad Sci. 2005 Jun;1050:274-85. doi: 10.1196/annals.1313.029. Ann N Y Acad Sci. 2005. PMID: 16014543
-
Onconeuronal and antineuronal antibodies in patients with neoplastic and non-neoplastic pulmonary pathologies and suspected for paraneoplastic neurological syndrome.Eur J Med Res. 2009 Dec 7;14 Suppl 4(Suppl 4):156-61. doi: 10.1186/2047-783x-14-s4-156. Eur J Med Res. 2009. PMID: 20156748 Free PMC article.
-
Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options.Ann Neurol. 1995 May;37 Suppl 1:S102-13. doi: 10.1002/ana.410370711. Ann Neurol. 1995. PMID: 8968221 Review.
-
Anti-Ri-associated paraneoplastic ophthalmoplegia-ataxia syndrome in a woman with breast cancer: a case report and review of the literature.J Med Case Rep. 2020 Jun 12;14(1):67. doi: 10.1186/s13256-020-02410-z. J Med Case Rep. 2020. PMID: 32527295 Free PMC article. Review.
References
-
- Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison’s principles of internal medicine. New York: Mcgraw-hill Medical; 2008.
-
- Tampoia M, Zucano A, Antico A, Giometto B, Bonaguri C, Alessio MG, Radice A, Platzgummer S, Bizzaro N. Diagnostic accuracy of different immunological methods for the detection of antineuronal antibodies in paraneoplastic neurological syndromes. Immunol Invest. 2010;39(2):186–195. doi: 10.3109/08820130903513431. - DOI - PubMed
-
- Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanche JP, Confavreux C, Vighetto A, Renault-Mannel V, Michel D, Honnorat J. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol. 2000;48(1):105–108. doi: 10.1002/1531-8249(200007)48:1<105::AID-ANA16>3.0.CO;2-G. - DOI - PubMed
LinkOut - more resources
Full Text Sources